Nucleic-Acid-Based Targeted Degradation in Drug Discovery

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Targeted protein degradation (TPD) using proteolysis-targeting chimeras (PROTACs) is a key therapeutic strategy.
• Conventional PROTACs are limited to intracellular targets with accessible ligand-binding sites.

Purpose of the Study:

• To review emerging TPD strategies utilizing nucleic acids.
• To explore novel approaches for targeted degradation of RNA molecules.

Main Methods:

• Overview of nucleic acid-based modalities (e.g., aptamers, oligonucleotide mimics).
• Discussion of ribonuclease-targeting chimeras (RIBOTACs) as a novel degrader class.
• Analysis of design strategies, case studies, and applications.

Main Results:

• Nucleic acid-based approaches significantly broaden the scope of TPD.
• RIBOTACs represent a promising new modality for targeted RNA degradation.
• Emerging strategies address limitations of conventional TPD methods.

Conclusions:

• Nucleic acid-based TPD strategies offer versatile platforms for therapeutic development.
• Further research into RIBOTACs and other nucleic acid degraders holds significant potential.
• These advancements expand the druggable target space in drug discovery.